Chemo and immunotherapy before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple-negative breast cancer
- The main tumor must be at least 2 cm in size and cancer stage 2 or 3
- You must be able to do daily activities without help (ECOG score 0 or 1)
- Women who can become pregnant need a negative pregnancy test and must use effective birth control during treatment and for 6 months after
- You cannot have had breast cancer before or any other cancer in the last 5 years (except some easily treated skin cancers)
- You cannot have an autoimmune disease (like lupus) that needs treatment, or a weak immune system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a PARP inhibitor (olaparib) and a chemotherapy drug (paclitaxel) before surgery for early high-risk triple negative breast cancer that is HRD positive. It aims to shrink or eliminate the tumor to improve long-term outcomes.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.